Abcellera Biologics INC

AbCellera Biologics Inc. announced the pricing of an oversubscribed public offering of common shares and pre-funded warrants, raising approximately $200 million to fund its internal pipeline and general corporate purposes.

AbCellera Biologics Inc. announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, showing significant reductions in vasomotor symptoms and a favorable tolerability profile.

AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial for ABCL635, a non-hormonal treatment for menopausal vasomotor symptoms, on August 10, 2026, followed by an investor call.

AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals Incorporated to discover, develop, and commercialize multispecific T-cell engagers for autoimmune diseases.

AbCellera Biologics Inc. announced the appointment of Dr. Lynn Seely as an independent director to its Board of Directors.

AbCellera Biologics Inc. and Jazz Pharmaceuticals plc have entered into a preclinical research collaboration to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

AbCellera Biologics Inc. announced its Q2 2026 financial results, showing a significant decline in total revenue and an increased net loss, while also highlighting progress in its clinical programs and new strategic partnerships.

AbCellera Biologics Inc. reported its first quarter 2026 financial results, highlighting increased revenue and progress in its internal drug candidate pipeline, particularly with ABCL635.

AbCellera Biologics reported increased revenue but a wider net loss in Q3 2025, while advancing two antibody therapies into Phase 1 clinical trials and a third into IND/CTA-enabling studies.

AbCellera Biologics reports reduced operating losses and significant clinical pipeline advancements, initiating Phase 1 trials for two antibody therapies while maintaining a strong liquidity position.

AbCellera Biologics' Q1 2025 revenue decreased due to a shift towards internal programs, while R&D expenses increased as the company advances its pipeline.

AbCellera Biologics Inc. reported a net loss of $51.1 million for the third quarter of 2024, with revenue decreasing slightly and operating expenses increasing significantly due to impairment charges.

AbCellera Biologics Inc. reported a 161% revenue increase and reduced net loss in 2025, driven by a patent settlement and clinical pipeline advancements.

AbCellera Biologics Inc. files its annual report on Form 10-K, highlighting its focus on antibody drug discovery and development, advancements in its internal programs, and strategic partnerships.

AbCellera Biologics Inc.'s 2023 annual report details strategic investments in technology and internal programs, alongside a diversified partnership portfolio, while navigating a shift from COVID-19 related revenues.

John S. Montalbano, a Director of AbCellera Biologics Inc., purchased 10,000 shares of common stock on August 18, 2026 for $11.03 per share.

Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., purchased 37,200 shares of common stock on August 14, 2026 for $10.32 per share.

Michael R Hayden, a Director of AbCellera Biologics Inc., purchased 46,387 shares of common stock on August 12, 2026 for $10.37 per share.

Michael R Hayden, a Director of AbCellera Biologics Inc., reported a transaction in 50,000 shares of common stock on August 11, 2026.

Director Lynn Seely of AbCellera Biologics Inc. acquired stock options, with vesting scheduled over three years.

Victor Sandor, a Director at AbCellera Biologics Inc., has acquired stock options as part of his compensation, with vesting over three years.

AbCellera Biologics Inc. has announced its 2026 Annual Meeting of Shareholders will be held virtually on June 11, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

AbCellera Biologics Inc. will hold its annual meeting of stockholders on June 12, 2025, to elect directors, ratify the appointment of KPMG LLP as the independent auditor, and conduct an advisory vote on executive compensation.

AbCellera Biologics Inc. will hold its 2025 Annual Meeting of Shareholders virtually on June 12, 2025, to elect directors, ratify the appointment of KPMG LLP, and conduct a non-binding advisory vote on executive compensation.

AbCellera Biologics Inc. will hold its annual meeting of stockholders on June 13, 2024, to elect directors, ratify the appointment of KPMG LLP, and approve executive compensation.

AbCellera Biologics will hold its 2024 Annual Meeting of Shareholders virtually on June 13, 2024, to vote on director elections, auditor ratification, and executive compensation.